Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Is Immuron (ASX: IMC) quietly staging a turnaround? PROIBS launch sparks 20% rally Immuron (ASX: IMC) shares jumped 20 percent following its IBS product launch. Can the PROIBS rollout turn this microcap into a digestive health contender? byVenkateshOctober 26, 2025